To amend title XVIII of the Social Security Act to reform the payment rules regarding skin substitute products.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill expands a appropriation, compliance mandate provision: 2. Findings Congress finds the following: Skin substitute products are advanced biological therapies used to treat chronic, non-healing wounds, such as diabetic and expands a reporting req, compliance mandate, definition change provision: 3. It relies on compliance mandates, appropriations, reporting requirements, and definition changes. The main policy areas are Healthcare.
Who Benefits and How
The available clause analysis does not identify a specific beneficiary group.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Expands a appropriation, compliance mandate provision: 2. Findings Congress finds the following: Skin substitute products are advanced biological therapies used to treat chronic, non-healing wounds, such as diabetic...
- Expands a reporting req, compliance mandate, definition change provision: 3.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for primary purpose and policy domains.
At a Glance
What This Bill Does
The bill expands a appropriation, compliance mandate provision: 2. Findings Congress finds the following: Skin substitute products are advanced biological therapies used to treat chronic, non-healing wounds, such as diabetic and expands a reporting req, compliance mandate, definition change provision: 3.
Key Policy Areas
Healthcare
Primary Purpose
The bill expands a appropriation, compliance mandate provision: 2. Findings Congress finds the following: Skin substitute products are advanced biological therapies used to treat chronic, non-healing wounds, such as diabetic and expands a reporting req, compliance mandate, definition change provision: 3.
Policy Domains
Sponsors
Legislative Progress
IntroducedMr. Cassidy introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology